COMP <GO>
SIBN vs ABBV // GROSS PROFIT MARGIN
SI-BONE Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SIBN 3
— ABBV 8
▲ GROSS PROFIT MARGIN LEADER: SIBN
LAST: $22.41 (+2.66%) • MKT CAP: $1.00B
gross-margins
79.60%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SIBN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SIBN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 79.60% | 70.20% | +9.40 | SIBN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.30% | 29.00% | -39.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.90% | 3.47% | -4.37 | ABBV | /fcf-yield <GO> |
| Operating Margin | -11.10% | 24.60% | -35.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -9.40% | 6.90% | -16.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 8.60% | +11.60 | SIBN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.73 | 5.33 | +3.40 | SIBN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 65.1 | -6.45 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.00B | $513.86B | -$512.86B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SIBN REV | ABBV REV | SIBN GROSS % | ABBV GROSS % | SIBN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $200.9M | $61.16B | 79.6% | 70.2% | -$9.1M | $17.82B |
| FY 2024 | $167.2M | $56.33B | 79.0% | 70.0% | -$22.9M | $17.83B |
| FY 2023 | $138.9M | $54.32B | — | — | -$18.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SIBN // BETA —
ABBV // BETA 1.15